Skip to main content

AS/Spondyloarthritis

NSAID Safety with COVID-19 Infection

May 12, 2021

NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.



Early in the pandemic there was an unfounded directive from the French government suggesting that non-

Read Article

Insurers Bet Big on Bribing Patients

Madelaine Feldman, MD, and Jay Salliotte
May 11, 2021

Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division. They could receive a $500 debit card from Cigna, with just one string attached: they would have to switch to a different medication, one preferred by the insurer

Read Article

RheumNow Podcast – Falling or Falling in Love?

May 06, 2021

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Read Article

Drug Monitoring Ineffective with Infliximab Treatment

May 05, 2021

The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not. A randomized trial compared TDM to no TDM in patients receiving infliximab for chronic immune-mediated inflammatory diseases (

Read Article

RheumNow Podcast – Uppers and Downers

Apr 30, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article

Seven Year Delay in Diagnosing Spondyloarthritis

Apr 29, 2021

A large patient cohort study suggests that the mean diagnostic delay (DD) in European axial spondyloarthritis (axSpA) patients is 7.4 years, moreso in women and younger patients.



An online survey of 2,652 patients from 13 countries (European Map of Axial Spondyloarthritis - EMAS)

Read Article

Golimumab Effective in non-radiographic Axial Spondyloarthritis

Apr 26, 2021

The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA).  After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein

Read Article

Diagnostic Delay in Spondyloarthritis

Apr 22, 2021

Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.



From a total of 64 studies identified the reported mean delay in diagnosing

Read Article

BSRBR: Demyelinating Disease Following Anti-TNFα Therapy

Apr 21, 2021

Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally incrased by taking TNFi therapy. 



From their large registry (n=13,489) they

Read Article

Broadalumab Efficacy in Axial Spondyloarthritis

Apr 19, 2021

Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).

Read Article

RheumNow Podcast – Combination Biologics

Apr 16, 2021

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Read Article

IL-23 Targeting for Enthesitis in Psoriatic Arthritis

MedPage Today
Apr 13, 2021

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.



At week 24, 45% of patients receiving subcutaneous guselkumab every 4 weeks and 50% of those given the medication

Read Article

Low Risk of Malignancy with Secukinumab

Apr 12, 2021

Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).



Safety data from 10,685 psoriasis, 2,523 PsA and

Read Article

DMARD Dropouts During COVID-19

Apr 12, 2021

A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do

Read Article

RheumNow Podcast – Mistakes with Steroids

Apr 08, 2021

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

Read Article

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Apr 02, 2021

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Mar 31, 2021

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.



Data derived from the retrospective

Read Article

HLA B27 Iritis - RNL 2021 Highlights

Mar 31, 2021

The Spondyloarthritis Advances pod presented during the RheumNow Live 2021 conference featured three speakers, including an excellent lecture by Dr. Robert Wang, ophthalmology, on HLA B27 iritis and practical tips for rheumatologists. 



I interviewed Dr. Wang and below are his five

Read Article
Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi

Dr. John Cush @RheumNow( View Tweet )

Mar 31, 2021
Want to ask a question for the RheumNow Podcast? Record your question in 1 minute or less and we may feature it on an upcoming episode. https://t.co/hOWU67uY1Y https://t.co/ooph09KuL9
Dr. John Cush @RheumNow( View Tweet )
Mar 22, 2021
Spondyloarthritis faculty panel with audience Q&A #RNL2021 https://t.co/iSosAtHLCZ
Dr. John Cush @RheumNow( View Tweet )
Mar 21, 2021
Dr. Artie Kavanaugh leading the spondyloarthritis pod focusing on enthesitis and dactylitis management. #RNL2021 https://t.co/NCUwabTXVd
Dr. John Cush @RheumNow( View Tweet )
Mar 21, 2021
Join me at the @RheumNow SpA session happening now! #rheumatology #spondyloarthritis #ankylosing https://t.co/CTLq0xWQys
Nigil Haroon MD, PhD 💎🦜🌎🩺🔬 @NigilHaroon( View Tweet )
Mar 21, 2021
News Feature: Are You a Super Rheum? https://t.co/LsGpFNXlkp https://t.co/Q9iojEQNqL
Dr. John Cush @RheumNow( View Tweet )
Mar 19, 2021
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH

Dr. John Cush @RheumNow( View Tweet )

Mar 19, 2021
×